Contribution
My Lords, I will speak to Amendment 97, in the name of the noble Baroness, Lady Scott of Needham Market, to which I added my name. I will speak also to my Amendment 99 in this group, to which the noble Baroness has put her name, for which I am grateful.
Both these amendments seek to strengthen Clause 25 and address the critical question of whether the neighbourhood health framework is sufficiently clear about people whose conditions require continuing co-ordinating support but may not always be visible in immediate access or activity measures. The answer, in short, is no, and this is the view held by a host of dedicated organisations, including Alzheimer’s Research UK, Parkinson’s UK, the Migraine Trust and the Neurological Alliance, to name a few.
Amendment 97 seeks to build on the existing architecture of neighbourhood care by requiring neighbourhood health plans to set out how the needs of people with long-term, complex or fluctuating health conditions are to be met—in particular, the needs of those suffering from neurological conditions, which impact one out of every six people in England and span more than 600 different conditions, ranging from sudden onset issues such as stroke or traumatic brain injury to progressive diseases such as Alzheimer’s and Parkinson’s, to intermittent conditions such as migraine and epilepsy. I should declare that I suffer from migraine and that epilepsy impacts one of my children, but is, thankfully, well controlled. With this hugely significant and diverse group in mind, Amendment 99 would require guidance issued by the Secretary of State under Clause 25(4) to cover the identification of unmet needs, clinical pathways, workforce and service capacity, and accountability arrangements for services supporting those with long-term, fluctuating health conditions.
These amendments would support earlier recognition, co-ordinated care and appropriate planning across primary care, and community and specialist services, while preserving local flexibility. Crucially, they would set measurable improvement objectives and make organisational responsibility clear. These amendments are proportionate. They would strengthen the existing NHP process, rather than creating a separate, disease-specific plan or treatment entitlement. By keeping the legal duty broad and non-exhaustive, they would avoid disease-by-disease legislation.
Crucially, these amendments would give neurological conditions a clear policy home within neighbourhood planning. Without greater clarity, under-recognised conditions risk being overlooked within broad population priorities. A prime example of this is migraine: a neurological condition that impacts 10 million of us across the UK, for which treatment is underfunded, inconsistent and, at times, misguided, and shows huge regional disparities. Migraine is generally a high-volume but low-complexity condition, meaning that, if optimal treatment pathways are followed efficiently, capacity can be freed up in other parts of the health service.
Let me illustrate this. The NHS currently spends around £150 million a year on directly treating migraine, a condition that carries an annual cost to this country of £10 billion to £12 billion, of which more than £1 billion is incurred by the health service itself. How so? We currently have more than 5 million undiagnosed migraineurs, resulting in 2.5 million to 3 million primary care appointments in England per year, 40,000 hospital admissions per year and a huge increase in visits to A&E since the pandemic. Only a third of people diagnosed with migraine are prescribed basic preventive medication within one year of diagnosis. This is hugely inefficient and frustrating, both for the patient and the NHS. The impact on the workforce and the economy is eye-watering, with lost working days and reduced productivity currently running at £8 billion to £10 billion a year.
Migraine represents an important test for whether the reforms in the Bill will improve care. As for many neurological conditions, there is currently a postcode lottery of care for migraine. The Migraine Trust tells us that only 26 of England’s 42 integrated care systems have a specialised headache clinic.
In conclusion, Amendments 95 and 97 offer critically needed safeguards during NHS restructuring and health devolution—particularly during the transition period, with the uncertainty around national clinical leadership and analytical capacity—and where the less visible conditions lack clear ownership. I hope the Minister and her department will accept these amendments as both constructive and proportionate, or at the very least set out equally robust commitments through statutory guidance.